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Background: There is a considerable variation in the phenotype and course of the disease in cystic ﬁbrosis (CF) even in patients with the same
CFTR genotype, suggesting that other factors are important for prognosis. Mannose-binding lectin (MBL) has been proposed as one of these
factors. We therefore investigated the inﬂuence of MBL2 gene variants on disease severity, age at acquisition of Pseudomonas aeruginosa, and
survival in CF patients.
Methods: MBL2 variants were studied in 106 Argentinean pediatric CF patients carrying two severe CFTR mutations. Clinical phenotype was
deﬁned according to the Shwachman score and lung function tests. Age at infection with P. aeruginosa and age at death were also recorded.
Results: MBL insufﬁciency was associated with a 3.5-fold risk of having a severe phenotype (CI 95%: 1.2–10.3, p = 0.03). It was also associated
with an earlier onset of infection with P. aeruginosa (p = 0.035). No statistically signiﬁcant differences were found in FEV1 and survival.
Conclusions: MBL insufﬁciency was associated with detrimental progression of the disease. These results together with previous ﬁndings suggest
that the effect of MBL2 expression may be a major determinant of the severity of the clinical phenotype in patients with CF.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Mannose-binding lectin; MBL2; Modiﬁer gene; Phenotype; Polymorphism1. Introduction
Cystic fibrosis (CF) is an autosomal recessive multisystemic
disease caused by mutations in the gene encoding the Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR).
Although CF is a monogenic pathology, there is considerable
variation in the phenotype and course of the disease. Phenotypic
variation in CF can be attributed to several sources, including
different mutations in the CFTR gene, other genetic factors,
environmental factors, random events, and interactions between
any of these [1]. CFTR mutations mainly determine the degree⁎ Corresponding author.
1 These authors have contributed equally to this work.http://dx.doi.org/10.1016/j.jcf.2014.07.012
1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Aof exocrine pancreatic dysfunction, impaired sweat chloride
concentration, and malformation of the male reproductive
system. Nevertheless, the severity of lung disease, which is the
major cause of morbidity and mortality in CF, is poorly
correlated with the CFTR genotype. The phenotypic variability
is seen even among patients with the same mutations in the
CFTR gene, strongly suggesting the existence of modulating
factors that are important for patient prognosis.
In CF, the lung disease is characterized by a chronic infection
with typical pathogens such as Pseudomonas aeruginosa,
Staphylococcus aureus, and Burkholderia cepacia, which leads
to chronic inflammatory damage of lung tissue and progressive
loss of lung function. Therefore, it is important to recognize the
factors that influence susceptibility to infection.ll rights reserved.
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mannose-binding lectin 2 (MBL2) gene [2]. MBL2 encodes
mannose-binding lectin (MBL), a protein of the innate immune
system that is synthesized by the liver and functions as an
opsonin and complement activator. Through the lectin domain,
MBL binds to carbohydrate structures on a wide range of
bacteria, viruses, fungi, and parasites. Thereby, MBL activates
the complement pathway lectins with subsequent opsonization
or direct lysis of the target [3]. Although MBL is a serum
protein, it accumulates in the lungs during acute inflammation
in quantities sufficient to promote phagocytosis and activate
complement [4]. MBL is biologically active in the oligomerized
form. In the general population, levels of oligomerized MBL in
the blood vary dramatically due to the presence of certain
variants in the MBL2 gene [5]. The presence of the X allele at
position −221 of the MBL2 promoter produces a lower amount
of circulating MBL than that found in the presence of the Y
allele. In addition, missense mutations in exon 1 abolish the
assembly of the protein into its biologically active form [6–8].
Such mutations include substitution of glycine for aspartic acid
at codon 54, glycine for glutamic acid at codon 57, and arginine
for cysteine at codon 52. These allelic variants are called B, C,
and D, respectively, and are usually collectively referred to as 0
(zero) alleles, while the wild-type allele is labeled A. Each
genetic variant reduces the amount of functional MBL between
5 and 10 times [9]. It has been shown that low levels of MBL in
the blood are associated with susceptibility to infections in
various clinical settings [10].
Taking into account that lung infections are the main cause of
morbidity and mortality in CF, MBL2 has been proposed as a
modulator of clinical severity in this disease. Assessing different
markers of clinical severity, several authors have investigated the
role of MBL deficiency as a modifying factor in CF [2,11–13].
Although the results of these studies have not been entirely
consistent, according to a recent meta-analysis the available
evidence suggests that MBL insufficiency is associated with the
severity of CF lung disease [14]. Nevertheless, studies in
pediatric populations have not been able to clearly demonstrate
the influence of MBL on lung phenotype [15–17]. To date, the
vast majority of association studies of MBL and CF have been
performed in populations of developed countries of North
America and Europe [2,11,12,15–19] and little is known about
populations in developing regions, such as Latin America [20]. In
these populations, there is a higher proportion of people with low
incomes and lack basic services, affecting access to expensive
medications, nutritional status, and adherence to treatment.
The aim of this study was to assess the influence of
structural and promoter variants in MBL2 on disease severity,
age at acquisition of P. aeruginosa, and survival in Argentinean
children with cystic fibrosis.
2. Materials and methods
2.1. Study population and data collection
A total of 106 CF patients carrying two severe mutations in the
CFTR gene were retrospectively evaluated. All patients werediagnosed and followed-up at the Pulmonology Department of a
public tertiary-care pediatric center, Hospital de Pediatría “Prof.
Dr. Juan P. Garrahan,” in Buenos Aires, Argentina. Among the
106 patients, 10 sibling pairs were included. Measurements of
forced expiratory volume in one second (FEV1) and forced vital
capacity (FVC) were collected. Age at first positive culture of
P. aeruginosa and age of death were recorded. Repeated FEV1
measurements at 7, 8, 9, and 10 years of age were available in 28
patients.
CFTR mutations had been previously determined by molec-
ular methods routinely used at the Laboratory of Molecular
Biology of the same hospital (PCR for ΔF508 and Oligonucle-
otide Ligation Assay–Cystic Fibrosis Genotyping Assay;
Celera-Abbott for 32 CFTR mutations). In order to exclude
variables that could affect the disease phenotype, all patients
included in this study had pancreatic insufficiency (PI) and
carried severe CFTR mutations on both alleles. Patients reported
as having PI but carrying at least one CFTR mutation typically
associated with pancreatic sufficiency were excluded. Of the 106
patients, 75 were homozygous for the severe mutation ΔF508,
27 were heterozygous for ΔF508 together with another severe
mutation, and four patients carried two severe non-ΔF508
mutations.
A written informed consent approved by the Ethics
Committee of the Hospital was obtained from the parents of
each participant.2.2. MBL2 genotyping
DNA samples extracted from peripheral blood leukocytes by
standard procedures were used to characterize MBL2 genetic
variants. Genotyping was performed using PCR restriction
fragment-length polymorphism (PCR-RFLP) assays as de-
scribed elsewhere [21]. Briefly, BanI and HhaI restriction
enzymes were used for analysis of structural variants and SacII
enzyme was used for promoter variants. The resulting fragments
were analyzed on 3% Agarose 1000 gel (Invitrogen) stained
with ethidium bromide.
Patients with genotypes associated with a high production
of MBL (YA/YA, YA/XA) were grouped as MBL-sufficient
(MBL-Suf) and patients with genotypes associated with an
intermediate and low production of MBL (XA/XA, YA/0, XA/0,
0/0), as MBL-insufficient (MBL-Ins), in a similar approach as
described by Yarden et al. [12].2.3. Clinical phenotype
Lung function testing involves voluntary breathing maneuvers
that are usually not possible in children until 5–6 years of age.
Therefore, in our study, only patients between 5 and 9 years of
age (n = 66) were considered for association analysis of MBL2
with disease phenotype in order to obtain a homogeneous group
with as many lung function studies as possible. The clinical
phenotype of these patients was defined as mild, moderate, and
severe based on the Shwachman score [22] and lung function
studies when available (Table 1).
Table 2
Baseline demographic and clinical characteristics of CF patients.
Total MBL-Suf MBL-Ins p
Age at diagnosis (years) 1.4
(0–12)
1.6
(0–12)
1.2
(0.02–12)
0.477 a
Sex (male:female) 44:62 26:31 18:31 0.355 b
Health Care Insurance 61/106 37/57 24/49 0.098 b
Pancreatic insufficiency 106/106 57/57 49/49 –
Meconium ileus 17/99 6/54 11/45 0.080 b
CFTR mutations DF508/DF508 75 41 34 0.499 b
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The Shwachman score was calculated by pediatric
pulmonologists with expertise in CF. This score is divided into
four domains, namely: General activity, physical examination,
nutrition, and radiological findings, each having five possible
subscores according to the degree of impairment. The scores of the
four domains are summed to obtain the final score, fromwhich the
condition of the patient is categorized as excellent (86–100), good
(71–85), average (56–70), poor (41–55), or severe (≤40) [23].DF508/other c 27 15 12
Other c/other c 4 1 3
Ranges are indicated between brackets.
a p value determined by t test.
b p values determined by the Chi square test.
c Other severe mutations: 1717-1G-NA, G542X, N1303K, W1282X, G551D,
DI507, 3659delC.2.3.2. Lung function test
Testing was performed on the Vitalograph® spirometer at the
Lung Function Laboratory of the Pulmonology Department in
patients over 5 years of age. Forced vital capacity (FVC, FEV1,
and FEF 25–75%) and flow-volume curves were done following
the American Thoracic Society guidelines [24]. FEV1 was
expressed as a percentage of the predicted values for sex, height,
and age. Predicted values were based on the formula of Knudson
et al. [25] for those over the age of 10 years, and Polgar and
Varuni [26] for those 6–10 years of age.2.4. Statistical analysis
Contingency tables and Fisher's exact test were used for
association studies, and relative risk was calculated. The t test was
used to compare continuous data between the two groups of
patients. Survival analysis was performed using the Kaplan–Meier
method and assessed by the log-rank test. For all analyses SPSS
statistical package was used. A p value of 0.05 or less was
considered significant.3. Results
3.1. Patient demographics and clinical features
Baseline characteristics of the pediatric CF cohort are shown in
Table 2. A total of 106 patients born between 1973 and 2009 were
included. Thirty-one patients were deceased. The mean age at
death was 7.5 years (median: 6.5 years, range: 1.7 to 19.8 years).
Regarding age at P. aeruginosa infection, 50% of patients
presented positive cultures before the first year of life. Spirometric
results were available in 50 patients. Mean FEV1 was 70% of that
predicted for sex, height, and age (range: 18 to 119%). Mean FVC
was 83% (range: 32 to 126%). Demographic and clinical variables
did not show significant differences when comparing MBL-Suf
and MBL-Ins patients (Table 2).Table 1
Classification of the clinical phenotype in 66 CF patients.
Clinical phenotype Shwachman score Pulmonary function tests
Mild 55–75 FVC N 80% FEV1 N 70%
Moderate 35–54 FVC 60–79% FEV1 40–69%
Severe b35 FVC b 59% FEV1 b 39%
Abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume in
1 s.3.2. Distribution of MBL2 gene variants in CF patients
Structural and promoter variants in theMBL2 gene were typed
in 106 CF patients with two severe mutations in the CFTR gene.
Frequencies are described in Table 3. For the structural variants,
36.5% of the patients were A/0 and 9.3%, 0/0. For the promoter
variants, 27.6% were Y/X and 2%, X/X. The distribution of
MBL2 genotypes was found in Hardy–Weinberg equilibrium for
both structural (p = 0.39) and promoter (p = 0.79) variants.
3.3. Effect of the MBL2 genotype on disease severity
In 66 patients the clinical phenotype was established.
Twenty-one were classified as severe and 45 as non-severe
(including moderate and mild). According to the MBL2
genotype, 39 were MBL-Suf and 27, MBL-Ins.
MBL insufficiency was significantly more frequent in the
group of patients with a severe phenotype (62%) than in the
group with a non-severe phenotype (31%, p = 0.03). MBL
deficiency was associated with a 3.5 times higher risk of having
a severe phenotype (95% CI: 1.2–10.3) (Fig. 1).
3.4. Influence of the MBL2 genotype on lung function
Measurements of FEV1 and FVC, considered for the assigna-
tion of the clinical phenotype, were available in 50 patients, 32
MBL-Suf and 18MBL-Ins. No differences were found in themean
values of FEV1 and FVC between both groups (FEV1: 71% vs
69%; FVC: 85% vs 84%, respectively).
3.5. Follow-up of lung function
In a group of 28 patients, 17 MBL-Suf and 11 MBL-Ins, FEV1
measurements were collected at 7, 8, 9, and 10 years of age. At
7 years, lung function of MBL-Ins patients was significantly
reduced compared with MBL-Suf patients (p = 0.028). FEV1
values in MBL-Ins patients were below those of MBL-Suf
patients, although these differences were not statistically signifi-
cant (Fig. 2).
Table 3
Genotype frequencies of MBL2 gene polymorphisms in CF patients.
MBL2 genotype CF patients
n %
Structural
A/A 52 54.2
A/B 22 22.9
A/D 13 13.5
All A/0 a 35 36.5
B/B 6 6.3
B/D 3 3.0
All 0/0 b 9 9.3
Total 96 100
Promoter
Y/Y 68 70.8
Y/X 26 27.1
X/X 2 2.1
Total 96 100
Haplotypes
YA/YA 35 36.5
YA/Y0 26 27.1
Y0/Y0 8 8.3
YA/XA 15 15.6
XA/Y0 9 9.4
XA/XA 2 2.1
Y0/X0 1 1.0
Total 96 100
For estimation of genotypic frequencies, only the eldest sibling of each of the
ten pairs of siblings was included.
a A/0 = A/B + A/D.
b 0/0 = B/D + B/D.
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Fig. 2. Lung function in patients between 7 and 10 years old. Patients were
stratified according to whether they belonged to the MBL-Suf group (n = 17,
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Data on the first positive culture for P. aeruginosa were
available in 76 patients; 43 were MBL-Suf and 33 MBL-Ins.
The age at first P. aeruginosa infection was significantly lower
in the MBL-Ins group than in the MBL-Suf group (p = 0.035)
(Fig. 3).MBL-Suf
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Fig. 1. Distribution of patients with severe and non-severe phenotypes inMBL-Ins
and MBL-Suf groups. Among the 21 patients with a severe phenotype, 13
belonged to the MBL-Ins group (red bars) and 8 to the MBL-Suf group (green
bars). Of the 45 patients with a non-severe phenotype, 14 were MBL-Ins and 31
MBL-Suf. The association study was tested using the Fisher exact test (p = 0.03).3.7. MBL2 genotype and survival
Kaplan–Meier survival curves were plotted to assess the
distribution of age at death in 82 patients; 46 were MBL-Suf
and 36 MBL-Ins. No statistically significant differences were
found in age at death between MBL-Suf and MBL-Ins groups
(log-rank test, p = 0.482).p =  0.035
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Fig. 3. Kaplan–Meier plot for time to first positive culture of P. aeruginosa.
The proportion of patients free of infection with P. aeruginosa versus age is
plotted for MBL-Suf (n = 43, green line) and MBL-Ins (n = 33, red line). The
survival probability differences were tested using the log-rank test (p = 0.035).
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The course of the disease in CF patients is highly variable,
even among those with the sameCFTR genotype. Modifier genes
as well as environmental factors are thought to contribute to this
variability. In the present study, we assessed the influence of
MBL2 gene variants on disease severity, age at acquisition of
P. aeruginosa, and survival in a series of children with CF. To
exclude variables that could affect the phenotype, the following
considerations were taken into account: i) patients belonged to a
single medical center to reduce possible variability in the status of
the disease caused by differences in treatment and measurement
of clinical parameters; ii) all patients had two severe mutations to
minimize the effect of the CFTR genotype on the disease;
iii) for the analysis of association ofMBL2 gene variants with the
clinical phenotype only patients between 5 and 9 years were
included in order to obtain a homogeneous group with as many
lung function studies as possible.
According to the effect on protein level, MBL2 genotypes
are classified into different groups. Some studies use high,
intermediate, and low MBL expression groups, whereas most
studies classify the genotypes into MBL-sufficient and MBL-
insufficient groups [9,14,16,27]. The latter classification was
used in the present study. Grouping according to genotype
instead of protein levels may lead to clearer results, since
genotype is a non-variable parameter [15].
Up to now, in the vast majority of studies on MBL2 and CF,
the lung phenotype was used as a marker of clinical severity
[2,12,13,15–17]. In this line, a recent meta-analysis revealed a
significant correlation between MBL insufficiency and reduced
FEV1 in adult cohorts [14]; however, in five pooled pediatric
cohorts no significant effect of MBL2 genotype on FEV1 was
observed [14]. In fact, Muhlebach et al. [17] suggested that the
effect of MBL insufficiency on lung function may become
apparent after adolescence.
In the present study, in addition to lung involvement
measured by FEV1, we describe the global clinical phenotype
based on the Shwachman score and lung function studies. The
Shwachman score remains a useful tool for monitoring the severity
of cystic fibrosis, adequately reflecting functional impairment as
well as chest radiography and tomography changes [23]. This
allows us to classify patients as mild, moderate, and severe in
a more objective manner. We found that patients with MBL2
genotypes associated with low production of protein had an
increased risk of presenting a severe phenotype, 3.5 times higher
than those in the MBL-Suf group. Nevertheless, there was no
difference in the FEV1 value between MBL-Suf and MBL-Ins
patients, probably due to the fact that most patients who lacked data
on lung function had a severe phenotype.
In the group of 28 patients who had a follow-up of lung function
for at least four years, FEV1 at 7 years of age was significantly
reduced in MBL-Ins patients compared with MBL-Suf patients. In
the follow-up, there was a trend towards maintaining reduced lung
function in the MBL-Ins group. Garred et al. [2] observed in a
cohort of patients of varied ages followed for 9 years that lung
function remained significantly reduced in MBL-Ins patients
compared with those that were MBL-Suf. In a multicenter study ofpediatric patients, Dorfman et al. [16] found that in both groups at
10 years of age FEV1 was similar but that the rate of decline of
FEV1 was significantly steeper in the MBL2 genotypes associated
with low expression [16]. Collectively, these data suggest that the
effect of MBL2 expression could be a critical determinant of the
severity of lung disease at a young age in CF patients.
In previous studies, MBL deficiency was associated with
earlier acquisition of P. aeruginosa [14,16]. In our series, although
most patients showed early ages at infection, in the analysis of
time to event it was observed that MBL-Ins patients presented an
earlier age at first infection of P. aeruginosa than those who were
MBL-Suf. This modulating effect probably reflects the critical role
ofMBL in the first defense against bacterial colonization. In recent
studies, deficiency of other proteins of the lectin pathway, such as
ficolins (FCNs) and MBL-associated serine proteases (MASPs),
also showed association with earlier onset of P. aeruginosa [19].
Survival studies have produced conflicting results, with
authors who claimed a lower survival rate in MBL-Ins patients
[18,28] and others who did not find such association [13,27].
Our analysis did not show statistically significant differences in
age at death between MBL-Suf and MBL-Ins patients.
Up to our knowledge, there are very few studies on CF
modifying factors in Latin-American countries where socioeco-
nomic conditions of patients seen at public hospitals are far from
ideal. One of them, by Faria et al. in a Brazilian CF population, did
not find association between MBL2 polymorphisms and lung
disease severity. However, the authors did not specify how patients
were grouped according to MBL2 genotype. In our series, we
observed the influence of MBL2 deficiency on the disease course,
similarly as described in developed countries of North America and
Europe [2,11,12,15–19]. Our study highlights the role of theMBL2
gene as a modulating factor in CF, determining the course of the
disease in addition to environmental factors.
Finally, in this group of CF patients, MBL insufficiency was
associated with detrimental progression of the disease. In addition
to the contribution to a better understanding of the pathogenesis of
CF, the recognition of modifiers such as theMBL2 gene paves the
way for the development of new therapeutic strategies. Although
MBL replacement therapy appears to be effective in restoring the
lectin pathway of complement in adults and children with low
MBL, there is still no evidence from randomized clinical trials
that show a beneficial effect in the treatment or prevention of
infections [14]. Moreover, genetic testing of modifying factors
such asMBLmay lead to early identification of at-risk patients, so
they can be closely monitored by their physicians [16] and receive
more intensive medical care.
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